Oncology Institute (DFPH) Gross Profit (2021 - 2026)

Oncology Institute (DFPH) has reported Gross Profit for 6 consecutive years, with $139.2 million the latest figure, recorded in Q1 2026.

• Gross Profit for Q1 2026 came in at $139.2 million, up 90.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $470.9 million (up 19.05% YoY), and the FY2025 annual result was $282.2 million, down 28.04% from the prior year.
• Gross Profit was $139.2 million for Q1 2026 at Oncology Institute, up from $75.4 million in the prior quarter.
• Over five years, Gross Profit peaked at $210.7 million in Q4 2024 and troughed at $27.8 million in Q1 2022.
• Average Gross Profit over 5 years is $74.1 million, with a median of $60.8 million recorded in 2022.
• Year-over-year, Gross Profit jumped 462.91% in 2024 and slumped 64.2% in 2025.
• Over 5 years, Gross Profit stood at $71.3 million in 2022, then sank by 47.52% to $37.4 million in 2023, then surged by 462.91% to $210.7 million in 2024, then plunged by 64.2% to $75.4 million in 2025, then soared by 84.52% to $139.2 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $139.2 million in Q1 2026, $75.4 million in Q4 2025, and $136.6 million in Q3 2025.